A Supreme Court chill across biosimilar 'skinny' labels could halt billions in Medicare savings

As generic drugmakers continue to petition the US Supreme Court to protect a longstanding precedent that allows them to carve out and market certain indications for a patented brand name drug — under what’s known as a “skinny” label — new research also raises questions about billions in savings lost from skinny biosimilar labels if courts leave this pathway in limbo.